FINAL PROGRAMMECROATIANSOCIETYFOR CLINICALPHARMACOLOGYAND THERAPY

CROATIANSOCIETYFOR CLINICALPHARMACOLOGYAND THERAPY

THURSDAY (19 April 2018)

Pre-Congress Workshop: Managed Entry Agreements for Oncology Drugs – The Way Forward in CEE

Faculty: Zoltan Kalo (HU), Tea Strbad (HR), Katarzyna Kolasa (PO), Slobodanka Bolanca (HR)

9:00 Zoltan Kalo (HU): MEAs - From Theory to Best Practice 10:00 Katarzyna Kolasa (PO): Implementation of MEAs in CEE

10:30 Coffee break

10:50 Tea Strbad (HR): 10 Years Experience of MEAs in Croatia 11:10 Slobodanka Bolanca (HR): MEAs - Innovative Industry Perspective11:30 Zoltan Kalo (HU): MEAs - From Theory to Best Practice (cont.)

12:30 Lunch (for registered Pre-congress Workshop participants)

Opening ceremony

14:00 Welcome address by Congress President, Dragana Atanasijevic14:10 Welcome address by Congress President, Dinko Vitezic14:20 Welcome address by Secretary of State at Serbian Ministry of Health,

Meho Mahmutovic14:25 Welcome address by Director of Serbian Health Insurance Fund, Sanja

Radojevic Skodric14:30 Welcome address by Head of WHO Country Office for Serbia, Zsofia

Pusztai14:35 Welcome address by Programme officer - EU policies / programming /

health / floods and DRM coordinator - European Union Delegation to the Republic of Serbia - European Commission, Maja Vuckovic Krcmar

CROATIANSOCIETYFOR CLINICALPHARMACOLOGYAND THERAPY

Importance of health economics and outcomes research for the sustainability of healthcare financing and patients wellbeing

Chairmen: Dragana Atanasijevic (SRB), Dinko Vitezic (HR)

14:40 Francois Meyer (FR): HTA without borders 15:05 Zoltan Kalo (HU): Where science and policy meet: Allocation and

efficiency of healthcare with special focus on CEE countries15:30 Goran Stevanovic (SRB): Health economic and patients outcomes

aspects of antimicrobial resistance: what should we do to improve? 15:55 Rok Hren (SI): ISPOR Health Science Policy Council support to the

ISPOR community and its research activities in the region

16:10 Coffee break

Sustainability of health care financing through DRG; The role of hospital management in the utilization of health economics in decision making

Chairmen: Ivan Jekic (SRB), Sinisa Varga (HR)

16:30 Rabia Kahveci (TK): Can we ensure value and improve performance by linking clinical quality and HTA?

16:45 Ferenc Kohalmi, Laszlo Imre (HU): Hungarian DRG - the Road from Introduction to 25 Years of Use

17:00 Davor Katavic (HR): Sustainability of healthcare financing in Croatia17:15 Simo Vukovic (SRB): Introduction of performance based payment in Serbia

17:30 Round table discussion: - The role of hospital management in the utilization of health

economic and quality standards in decision making; - Health economic aspects of DRG implementation in CEEModerator: Sinisa Varga (HR)Faculty: (1) Ferenc Vicko (SRB), (2) Tihomir Strizrep (HR), (3) Laszlo Lorenzovici (RO), (4) Sinisa Stevic (BIH), (5) Mira Djajic (BIH), (6) Dragan Korolija Marinic (HR)

18:55 Closure of Day 1

19:00 Welcome reception

FRIDAY (20 April 2018)

Antimicrobial resistance: influencing factors, economic and organizational implications

Chairmen: Ljiljana Pavlovic (SRB), Igor Francetic (HR)

9:00 Vesela Radonjic (SRB): Surveillance of antibiotic use in Serbia9:20 Krzysztof Łanda (PO): Pricing and economic tools for rational evaluation

and rationing of antibiotics utilization in modern health care9:40 Iva Kraljickovic, Robert Likic, Viktorija Erdeljic-Turk, Matea Radacic-Aumiler,

Ksenija Makar-Ausperger, Ivana Cegec, Iveta Mercep (HR): Impact of piperacillin / tazobactam shortage in 2017 on overall antibiotic expenditure at the University hospital center Zagreb

10:00 Vesna Suljagic (SRB): Is Antibiotic Overuse a Major Risk Factor for Clostridium difficile Infection in Sugical Patients?

10:20 Adrian Pana (RO): A Cost Minimization Analysis of a novel antibiotic vs SoC for the treatment of ABSSSI in Romania: resources and organizational outlooks

10:40 Coffee break

Importance of strategic collection and analysis of health data to improve quality and transparency of decision making processes

Chairmen: Milena Vasic (SRB), Slobodanka Bolanca (HR)

11:00 Darija Kisic Tepavcevic (SRB): Quality of life measures - tool for decision makers

11:20 Livio Garattini (IT): Immunotherapies for advanced melanoma: as promising as they are expensive?

11:40 Dragana Atanasijevic (SRB): Using data to drive decisions - from prioritization to health care expenses

12:00 Sinisa Varga (HR): Importance of eHealth and BIG DATA for maximizing opportunities in public healthcare

12:20 Desislava Mihaylova (BG): Big DATA in Oncology

CROATIANSOCIETYFOR CLINICALPHARMACOLOGYAND THERAPY

12:40 Zvonimir Durrigl (HR): From pharmacokinetics to Real World Evidence – an example of different data sources for value based evaluation

13:00 Lunch

Value based pricing and reimbursement policies - how to improve access to new technologies?

Chairmen: Natasa Bogavac (SRB), Livio Garattini (IT)

13:45 Pero Draganic (HR): Biosimilar medicines in Croatia and some CEE countries: determing the price and recompense

14:05 Thomas Griesbacher (A): Uptake of biosimilar products in Austria in relation to new legislation and the availablitiy of new biosimilars

14:25 András Harsányi (HU): Biosimilar drug policy in Hungary: Evaluating the results through infliximab's patent expiry

14:45 Andrej Janzic, Andreja Deticek, Igor Locatelli, Mitja Kos (SI): Understanding and relevance of criteria for reimbursement decision-making process

15:05 Omer Saka (BE): Road to Value in Bulgaria 15:25 Vladimir Zah (SRB): How to connect healthcare reimbursement claims

analyses to drive value based pricing decisions

15:45 Coffee break

Future of HTA in CEE – ‘nice to have’ or ‘must have’? Readiness of CEE national health administrations to fairly assess diverse new technologies

Chairmen: Dragana Atanasijevic (SRB), Zoltan Kalo (HU)

16:00 Mira Pavlovic (FR): Health Economic Evidence required for a meaningful reimbursement: reflection from HAS France

16:15 Jonathan D Campbell (US): Value Frameworks and US HTA Implementation

16:30 Luka Voncina (HR): HTA policy assessment in South East Europe - how to fix the gap?

16:45 Drazen Jelec (HR): Joint initiative to advance access to innovative medicines in the EU

17:00 Round table discussion: - Readiness and capacity of national health administration in CEE

countries to fairly assess / appraise diverse new technologies- Roles and responsibilitis of different stakeholders in Healthcare (e.g.

Health administration, Professional associaions, Patient Associations- Future of HTA in CEE – ‘nice to have’ or ‘must have’?Moderator: Zoltan Kalo (HU)Faculty: (1) Verica Jovanovic (SRB), (2) Dragana Vujicic (SRB), (3) Sinisa Stevic (BIH), (4) András Harsány (HU), (5) Guenka Petrova (BG), (6) Francois Meyer (FR), (7) Tea Strbad (HR)

18:15 Rountable Conclusion and Closure of Day 2

Poster session

Chairmen: Luka Voncina (HR), Aleksandar Knezevic (HR)

18:20 Alexandra Savova, Manoela Manova, Maria Vasileva, Valentina Petkova, Guenka Petrova (GB): Cost burden of direct acting antiviral agents for treatment of HCV in Bulgaria in 2016-2017

18:25 Natasa Duborija-Kovacevic, Milica Martinovic, Ines Banjari, Goran Belojevic, Bogdan Asanin, Vesna Buljan, Vesna Bilic-Kirin (MN, HR): The influence of socio-economic, demographic and cultural factors on the self-medication of children in Podgorica (Montenegro) and Osijek (Croatia)

18:30 Bojana Bozovic, Matija Radoicic, Slobodan Jankovic, Marina Kostic (SRB): Treating hemorrhoidal disease - how does it cost in pharmacoeconomic milieu in Serbia

18:35 Ivan Bosnjak, Marija Bosnjak (HR): Financial healthcare models - comparison between countries

18:40 Natasa Duborija-Kovacevic (MN), Bogdan Asanin, Tomasz Bochenek, Tanja Drincic, Benida Sahmanovic, Mitar Popovic: The investigation of drug shortages in Montenegro as the result of participation in cost action "European medicines shortages research network - addressing supply problems to patients (CA15105)''

18:45 Aleksandra Markovic, Gordana Prlincevic (SRB): Comparative analysis of the consumption of certain ATC groups of medicines and the costs in the period 2012 – 2017 in southeast Serbia

CROATIANSOCIETYFOR CLINICALPHARMACOLOGYAND THERAPY

18:50 Jasmina Arsic, Svetlana Stojkov, Natasa Jovanovic Ljeskovic (SRB): Financial Accessibility of Rare Disease Treatment for Pediatric Populations in Serbia

18:55 Kostadinka Kozareva, Sanja Saric Kuzina, Biljana Dimitrova (MK, HR): Pricing Policy in Macedonia in comparation to its referent countries

19:00 Samir Mukinovic (BIH): Accounting information based on modified basis in the function of budgeting the health insurance and limitation of the rights of patients

19:05 Jasmina Arsic, Dusanka Krajnovic (SRB): Availability of therapy for patients with rare diseases: what pharmacists think about it?

20:30 Congress dinner

SATURDAY (21 April 2018)

Specifics of health economic studies in different therapeutic areas (COPD and Diabetes)

Chairmen: Vlad Zah (SRB), Guenka Petrova (BG)

9:00 Maria Kamusheva, Konstantin Tachkov, Miglena Doneva, Valentina Petkova, Alexandra Savova, Konstantin Mitov, Guenka Petrova (BG): Epidemiology and cost of COPD therapy in Bulgaria

9:20 Konstantin Tachkov, Konstantin Mitov, Alexandra Savova (BG): Modelling the long term cost and results of COPD therapy

9:40 Maciej Niewada, Michał Jakubczyk (PO): Cost of cardiovascular diseases in diabetic patients in selected Central and Eastern European countries

10:00 Karmen Jansa, Petra Dosenovic Bonca, Alesa Lotric Dolinar, Jurij Stariha (SI): Overview of cardiovascular disease burden in patients with diabetes

10:20 Michał Jakubczyk, Maciej Niewada (PO): Cost of severe hypoglycaemia in selected European countries

10:40 Miodrag Bogdanovic (SRB): Cost-utility evaluation of new generation basal insulins

11:00 Coffee break

Sustainability of patient access to orphan drugs in CEE

Chairmen: Bojan Trkulja (SRB), Ljubica Suturkova (MK)

11:20 Dinko Vitezic, Tea Strbad (HR): Orphan medicines: where are we now?11:40 Davor Duboka (SRB): Patient access to orphan drugs and potential

improvements12:00 Andreja Deticek, Andrej Janzic, Igor Locatelli, Mitja Kos (SI): Access of

medicines for rare diseases in EU/CEE countries12:20 Biljana Indova, Ljubica Shuturkova, Rubin Zareski, Zoran Sterjev (MK):

Clinical and economic impact of introduction of adalimumab in treatment of RA patients in R.Macedonia

12:40 Marko Obradovic (GE): Use of real-world data to improve access to new technologies

CROATIANSOCIETYFOR CLINICALPHARMACOLOGYAND THERAPY

13:00 Lunch

Equity and equality of patient access to oncology treatments in CEE

Chairmen: Ljiljana Tasic (SRB), Danko Vrdoljak (HR)

13:40 Dragan Loncar, Filip Stojanovic (SRB): Availability of oncology treatments 14:00 Aleksandra Kapedanovska Nestorovska, Zoran Sterjev, Zorica Naumovska,

Aleksandra Grozdanova, Aleksandar Dimovski, Ljubica Suturkova (MK): Cost-effectiveness analysis of pertuzumab as first line neoadjuvant treatment option for patients HER2+ breast cancer in Republic of Macedonia

14:20 Nika Mardjetko, Andreja Deticek, Andrej Janzic, Igor Locatelli, Mitja Kos (SI): Access to new anticancer medicines in EU/CEE countries

14:40 Eve Hanna, Mondher Toumi, Claude Dussart, Borislav Borissov (BG), Olivier Dabbous, Karolina Badora, Pasqale Auquier: Funding breakthrough therapies – a systematic review and recommendations

15:00 Marija Seistrajkova (MK): Expensive drugs for hospital use in Macedonia - Pandora's box for health insurance

15:20 Coffee break

Legislative framework for co-financing arrangement for innovative health technologies - how could we move forward in CEE?

Chairmen: Vlad Zah (SRB), Bertalan Nemeth (HU)

15:40 Katarzyna Kolasa (PO): Do's and Don'ts for the implementation of innovative pricing&reimbursement models- key learnings from financing schemes of pharmaceutical and medical devices across EU settings

15:55 Dragana Janjic (SRB): Health policies development & complexities of break through innovation: DOES ONE SIZE FIT ALL?

16:10 Slobodanka Bolanca (HR): Which critieria play a major role in the feasibility and success of MEA implementation in SEE

16:25 Bojan Trkulja (SRB): Legislative obstacles and possible solutions for better access to innovation

16:40 Round table discussion: Major legislative and operational hurdles in effective implementation of co-financing and affordability programs in CEEModerator: Bertalan Nemeth (HU)Faculty: (1) Biljana Cukanovic (SRB), (2) Jovana Simanovic (SRB), (4) Luka Voncina (HR), (5) Natasa Grubisa (BIH), (6) Rabia Kahveci (TK), (7) Ljubica Suturkova (MK)

17:55 Rountable Conclusion

Congress Closing and Farewell

18:00 Closing address by Congress President, Dragana Atanasijevic18:10 Closing address by Congress President, Dinko Vitezic

SUNDAY (22 April 2018)

Open Joint Post Congress Meeting of Collaborative Associations - ISPOR, HDKFIT, INIFEZ, UZEFI

10:00 ISPOR Chapter Serbia: Feedback from the 8th Adriatic and 5th ISPOR Chapter Serbia Congress on Pharmacoeconomics and Outcomes Research

10:30 HDKFIT, INIFEZ: Proposal for topics and committees for the 9th Adriatic and 5th Croatian Congress on Pharmacoeconomics and Outcomes Research

11:00 ALL: Possible joint regional research activities

12:30 Lunch and departures

http://www.isporsrbija.com

obavestenja@isporserbia.com

MISSION, VISION, STRATEGY

ISPOR Chapter Serbia is a voluntary, non-profit association founded in May 2007

MISSION: Since its inception, ISPOR Chapter Serbia and all its members are guided by the mission focused on improving the health of all citizens of the Republic of Serbia by creating conditions for the provision of efficient, effective and equitable health care.

VISION: The Association ISPOR Serbia is a leader in the field of health economics, outcomes research procedure and use of research results in decision-making aimed at improving health.

STRATEGIC OBJECTIVES Strategic Platform of ISPOR Chapter Serbia is in line with the strategic objectives of the Global Association of ISPOR and has the 4 main strategic objectives:

SO1: Scientific and Research Excellence ISPOR Chapter Serbia is committed to strengthening the integrity, advancement, understanding, and use of health economics and outcomes research among researchers, health technology developers and assessors, regulators, health economists, health care policy makers, payers, providers, patients, populations, and society.

SO2: Member Engagement Through its worldwide membership and stakeholder groups, ISPOR Chapter Serbia has access to the ideas, knowledge, skills, and experiences that enable achievement of its mission. ISPOR Chapter Serbia offers membership benefits that are valued and essential in members' professional growth.

SO3: Education and Training Knowledge and skill building are at the core of the ISPOR Chapter Serbia mission. ISPOR will lead efforts to strengthen and expand capabilities in health economics and outcomes research.

SO4: Communication and Collaboration ISPOR will be a valued and reliable resource for translating knowledge into practice for decision makers and stakeholders, who include members, providers, payers, patients, professional societies, foundations, health authorities, the media, and others.

PLATINUM SPONSOR

GOLD SPONSORS

CROATIANSOCIETYFOR CLINICALPHARMACOLOGYAND THERAPY

SILVER SPONSORS

BRONZE SPONSOR

DONATORS

PREVIOUS CONGRESSES